Literature DB >> 11013440

Genetic lesions of bilirubin uridine-diphosphoglucuronate glucuronosyltransferase (UGT1A1) causing Crigler-Najjar and Gilbert syndromes: correlation of genotype to phenotype.

A Kadakol1, S S Ghosh, B S Sappal, G Sharma, J R Chowdhury, N R Chowdhury.   

Abstract

Uridine-diphosphoglucuronate glucuronosyltransferases (UGTs) are a family of enzymes that conjugate various endogenous and exogenous compounds with glucuronic acid and facilitate their excretion in the bile. Bilirubin-UGT(1) (UGT1A1) is the only isoform that significantly contributes to the conjugation of bilirubin. Lesions in the gene encoding bilirubin-UGT(1), lead to complete or partial inactivation of the enzyme causing the rare autosomal recessively inherited conditions, Crigler-Najjar syndrome type-1 (CN-1) and type 2 (CN-2), respectively. Inactivation of the enzyme leads to accumulation of unconjugated bilirubin in the serum. Severe hyperbilirubinemia seen in CN-1 can cause bilirubin encephalopathy (kernicterus). Kernicterus can be fatal or may leave behind permanent neurological sequelae. Here, we have compiled more than 50 genetic lesions of UGT1A1 that cause CN-1 (including 9 novel mutations) or CN-2 (including 3 novel mutations) and have presented a correlation of structure to function of UGT1A1. In contrast to Crigler-Najjar syndromes, Gilbert syndrome is a common inherited condition characterized by mild hyperbilirubinemia. An insertional mutation of the TATAA element upstream to UGT1A1 results in a reduced level of expression of the gene. Homozygosity for the variant promoter is required for Gilbert syndrome, but not sufficient for manifestation of hyperbilirubinemia, which is partly dependent on the rate of bilirubin production. Several structural mutations of UGT1A1, for example, a G71R substitution, have been reported to cause mild reduction of UGT activity toward bilirubin, resulting in mild hyperbilirubinemia, consistent with Gilbert syndrome. When the normal allele of a heterozygote carrier for a Crigler-Najjar type structural mutation contains a Gilbert type promoter, intermediate levels of hyperbilirubinemia, consistent with the diagnosis of CN-2, may be observed. Copyright 2000 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11013440     DOI: 10.1002/1098-1004(200010)16:4<297::AID-HUMU2>3.0.CO;2-Z

Source DB:  PubMed          Journal:  Hum Mutat        ISSN: 1059-7794            Impact factor:   4.878


  77 in total

1.  Correlation between bilirubin glucuronidation and estradiol-3-gluronidation in the presence of model UDP-glucuronosyltransferase 1A1 substrates/inhibitors.

Authors:  Jin Zhou; Timothy S Tracy; Rory P Remmel
Journal:  Drug Metab Dispos       Date:  2010-10-28       Impact factor: 3.922

2.  Bilirubin uridine diphosphate-glucuronosyltransferase variation is a genetic basis of breast milk jaundice.

Authors:  Yoshihiro Maruo; Yoriko Morioka; Hiroshi Fujito; Sayuri Nakahara; Takahide Yanagi; Katsuyuki Matsui; Asami Mori; Hiroshi Sato; Robert H Tukey; Yoshihiro Takeuchi
Journal:  J Pediatr       Date:  2014-03-17       Impact factor: 4.406

Review 3.  Stem cell therapy for inherited metabolic disorders of the liver.

Authors:  Susan Ellor; Thomas Shupe; Bryon Petersen
Journal:  Exp Hematol       Date:  2008-04-02       Impact factor: 3.084

4.  Developmental onset of bilirubin-induced neurotoxicity involves Toll-like receptor 2-dependent signaling in humanized UDP-glucuronosyltransferase1 mice.

Authors:  Mei-Fei Yueh; Shujuan Chen; Nghia Nguyen; Robert H Tukey
Journal:  J Biol Chem       Date:  2014-01-08       Impact factor: 5.157

5.  Hereditary spherocytosis coexisting with UDP-glucuronosyltransferase deficiency highly suggestive of Crigler-Najjar syndrome type II.

Authors:  Shigeo Iijima; Takehiko Ohzeki; Yoshihiro Maruo
Journal:  Yonsei Med J       Date:  2011-03       Impact factor: 2.759

6.  Case report by Toce and co-authors: Have all the reasons for poor morphine glucuronidation been addressed?

Authors:  Moshe Finel; Erkka Järvinen
Journal:  Br J Clin Pharmacol       Date:  2019-02-08       Impact factor: 4.335

7.  RNA-sequencing quantification of hepatic ontogeny and tissue distribution of mRNAs of phase II enzymes in mice.

Authors:  Hong Lu; Sumedha Gunewardena; Julia Y Cui; Byunggil Yoo; Xiao-bo Zhong; Curtis D Klaassen
Journal:  Drug Metab Dispos       Date:  2013-02-04       Impact factor: 3.922

8.  Induction of bilirubin clearance by the constitutive androstane receptor (CAR).

Authors:  Wendong Huang; Jun Zhang; Steven S Chua; Mohammed Qatanani; Yunqing Han; Riccarda Granata; David D Moore
Journal:  Proc Natl Acad Sci U S A       Date:  2003-03-18       Impact factor: 11.205

9.  Lifelong elimination of hyperbilirubinemia in the Gunn rat with a single injection of helper-dependent adenoviral vector.

Authors:  Gabriele Toietta; Viraj P Mane; Wilma S Norona; Milton J Finegold; Philip Ng; Antony F McDonagh; Arthur L Beaudet; Brendan Lee
Journal:  Proc Natl Acad Sci U S A       Date:  2005-03-07       Impact factor: 11.205

10.  Mapping of sudden infant death with dysgenesis of the testes syndrome (SIDDT) by a SNP genome scan and identification of TSPYL loss of function.

Authors:  Erik G Puffenberger; Diane Hu-Lince; Jennifer M Parod; David W Craig; Seth E Dobrin; Andrew R Conway; Elizabeth A Donarum; Kevin A Strauss; Travis Dunckley; Javier F Cardenas; Kara R Melmed; Courtney A Wright; Winnie Liang; Phillip Stafford; C Robert Flynn; D Holmes Morton; Dietrich A Stephan
Journal:  Proc Natl Acad Sci U S A       Date:  2004-07-23       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.